# A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

> **NCT02010970** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers
- Pharmacologic Action

## Interventions

- **DRUG:** Group 1 AZD3293
- **DRUG:** Group 2 AZD3293
- **DRUG:** Group 3 AZD3293
- **DRUG:** Group 1 Itraconazole
- **DRUG:** Group 2 Diltiazem
- **DRUG:** Group 3 Midazolam

## Key facts

- **NCT ID:** NCT02010970
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010970, "A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02010970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*